Sandrine Gaillard General Manager at Ipsen Germany “We have big ambitions in Germany and I am confident that we can make the turnaround happen quickly and advance our Dysport market share” Ipsen Germany: defining a robust path forward Dear colleagues, As we reach the end of phase II of Project Speywood, I wish to congratulate our extremely hard-working team in Germany, who have collaborated cross–functionally to devise a clear path forward for Dysport, which will not only benefit our market, but others across Europe too. Following the initial five–week diagnosis phase in Germany, we identified 11 core initiatives for our team to implement between now and the end of 2019. Phase II of the project has now enabled us to map out a clear framework as to how we will deliver these, including quick wins that we aim to achieve this year. Integral to our local plan has been a re–think of our current approach to customer segmentation, taking a much more data–driven and focused view on sales accounts and target HCPs. We are finalising more detailed segmentation guidelines, which have been developed in collaboration between French and German teams. We will share these guidelines imminently as we believe they are critical in helping reach our bold global ambition for Dysport. I look forward to meeting with members of the Project Speywood steering committee members later this week to re–group outcomes of phase II and align our respective action plans. We have big ambitions in Germany and I am confident that we can make the turnaround happen quickly and advance our Dysport market share. Sandrine Gaillard General Manager at Ipsen DACH Martin Gerwe Business Unit Head Targeting our full potential ”Over the past few weeks we have come together as a team and worked hard to better understand where our biggest potential growth areas are and, crucially, where we need to focus resources to hit our bold ambition. Our HCP adoption ladder means we now have a firm process to stratify our customers and take proactive steps to enable a shift in the prescribing mindset. We believe we have significant gains to make with those HCPs using Dysport as a second choice or as a first choice with sub–optimal dosing.“ Derk Bemeleit Director Strategic Commercial Capabilities Segmenting the market to achieve real results for Dysport ”Our belief is that Ipsen Germany can use Project Speywood to go one step beyond our competitors truly understanding the prescribing behaviour of our customers in Germany by gathering quality data and tailoring our approach. This is a much more advanced way of looking at the market and means we can uniquely combine data with KAM insight to drive success for this brand that constitutes our pillar in Neuroscience.“ Elke Walther Field Sales Manager Looking at the true potential of clinical centres in Germany ”As an outcome of Project Speywood we have agreed three distinct phases to alter our practice and enhance sales opportunities in Germany. Starting immediately, we will be rolling out clear action plans within our sales teams, focusing on quick win opportunities for the remainder of 2018. As we move into 2019 these will evolve into two further phases that will help deliver our longer–term targets for Dysport. I look forward to sharing our results and seeing our proposed guidelines being adopted by colleagues across Europe.“ CONFIDENTIAL – FOR INTERNAL USE ONLY